Developer of miniaturized, multi-specific soluble T-cell receptor (sTCR) biologics designed to enhance therapeutic precision in hard-to-treat cancers. The company's proprietary platform combines advanced AI and machine learning to accelerate the discovery and optimization of small-format soluble T-cell receptors, overcoming antigen heterogeneity and minimizing off-target toxicity, enabling oncology researchers and biopharma developers to precisely target diverse peptide-major histocompatibility complexes across multiple antigens and human leukocyte antigen types, offering a scalable and broadly applicable improved T-cell receptor technique.